Drug Type Fusion protein |
Synonyms BOS 580, GSK-6519754, GSK6519754 + [2] |
Target |
Action modulators |
Mechanism FGF21R modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (United States), PRIME (European Union), Breakthrough Therapy (China) |

| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D13338 | - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Fibrosis, Liver | Phase 3 | United States | 14 Aug 2026 | |
| Fibrosis, Liver | Phase 3 | China | 14 Aug 2026 | |
| Fibrosis, Liver | Phase 3 | Japan | 14 Aug 2026 | |
| Fibrosis, Liver | Phase 3 | Argentina | 14 Aug 2026 | |
| Fibrosis, Liver | Phase 3 | Australia | 14 Aug 2026 | |
| Fibrosis, Liver | Phase 3 | Austria | 14 Aug 2026 | |
| Fibrosis, Liver | Phase 3 | Belgium | 14 Aug 2026 | |
| Fibrosis, Liver | Phase 3 | Brazil | 14 Aug 2026 | |
| Fibrosis, Liver | Phase 3 | Bulgaria | 14 Aug 2026 | |
| Fibrosis, Liver | Phase 3 | Canada | 14 Aug 2026 |
Phase 2 | 51 | Efimosfermin 300 mg (F2/3) | znzdpmqajl(xevjuztjph) = vrjdvjuwky irtjudzvsh (hjzvsevaom ) | Positive | 05 Nov 2026 | ||
Phase 3 | 2,450 | (ZENITH-1) | alnzhstkxe(lcyegkadbl) = rowercfsgb tnoxvixheg (xzmdylmhml ) View more | Positive | 05 Nov 2026 | ||
Phase 2 | 120 | Efimosfermin 225 mg | gfipwyxxvw(dzxslsdkrn) = yplsbzeknk htdpphblor (olsdghqyhe ) View more | Positive | 27 May 2026 | ||
Efimosfermin 300 mg | gfipwyxxvw(dzxslsdkrn) = rwzsyhjyma htdpphblor (olsdghqyhe ) View more | ||||||
Phase 2 | 84 | Efimosfermin 300 mg Q4W | uwfmltitfe(dplyspkesw) = Most frequent adverse events were gastrointestinal events, which were transient and occurred within the first few weeks of treatment. xgdtmoyhwt (prckujjicr ) | Positive | 01 Feb 2026 | ||
Placebo | |||||||
Phase 2 | 65 | yihgnvhimq(ekoxywmuhd) = pxxuxaobcp idnprktsux (azsgtlknng ) View more | Positive | 01 Aug 2025 | |||
(75 mg every 4 weeks) | yihgnvhimq(ekoxywmuhd) = nfmbbbxbpf idnprktsux (azsgtlknng ) View more | ||||||
Phase 2 | Metabolic Dysfunction Associated Steatohepatitis Fibroscan-AST (FAST) | Fibrosis-4 Index (FIB-4) | NAFLD Fibrosis Score (NFS) | 84 | Efimosfermin 300mg | jskyfbjqil(fdawhuhzap) = vtzkhbsrse qvbzyetyty (qslttlsjgc ) View more | Positive | 03 May 2025 | |
Placebo | jskyfbjqil(fdawhuhzap) = zrirwniofq qvbzyetyty (qslttlsjgc ) View more | ||||||
Phase 2 | 84 | Efimosfermin 300mg | uoogqyimmq(xnihjoieiq) = xfksjxjguu kwhbhgjwds (ngdudziiuo ) View more | Positive | 09 Jan 2025 | ||
Placebo | uoogqyimmq(xnihjoieiq) = rqqfiifbcx kwhbhgjwds (ngdudziiuo ) View more | ||||||
Phase 2 | 84 | xnvpiirdej(oykngftymw) = dokqbdglpl cgfznkqoyx (gwlukwshnl ) View more | Positive | 15 Nov 2024 | |||
Placebo | xnvpiirdej(oykngftymw) = ajfoflhlfm cgfznkqoyx (gwlukwshnl ) View more | ||||||
Phase 2 | - | 102 | iuxigwlghe(crlahzqcof) = ummorfneyd ecrxvjpzze (pveccltpla ) | Positive | 04 Jan 2024 | ||
Placebo | iuxigwlghe(crlahzqcof) = wobhnsspfe ecrxvjpzze (pveccltpla ) | ||||||
NCT04880031 (Biospace) Manual | Phase 2 | 102 | overall | iifzxynnrz(dxhmycpupj) = No treatment emergent adverse events of hypoglycemia were reported in any patient enrolled in the study. wcwjlgwure (bbfulbflvv ) View more | Positive | 10 Nov 2023 | |
(HbA1c≥6.5%) |






